Research Progress on Immunization and Targeted Therapy for Triple-negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for approximately 15%–20% of all breast cancers. Patients with TNBC have a rapidly progressive clinical course, an earlier age of onset, faster distant recurrence, and more common visceral metastases as compared with other subtypes. However, treatment of...
Main Authors: | SHI Chao, ZHANG Xiangmei, LIU Yunjiang |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-07-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1426 |
Similar Items
-
Recent advances in targeted strategies for triple-negative breast cancer
by: Shuangli Zhu, et al.
Published: (2023-08-01) -
Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer
by: Tong L, et al.
Published: (2023-08-01) -
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01) -
Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer
by: LI Linrong, et al.
Published: (2023-01-01) -
Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand?
by: Emma E. Newton, et al.
Published: (2022-01-01)